NASDAQ:MNOV MediciNova Q2 2025 Earnings Results & Report $1.28 -0.05 (-3.83%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. MediciNova met analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.07 versus the -$0.07 consensus estimate, while revenue was $140 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call8:00 AM ET MediciNova EPS ResultsActual EPS-$0.07Consensus EPS -$0.07Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersMediciNova Revenue ResultsActual Revenue$140 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) MediciNova Q2 2025 Earnings FAQ Did MediciNova beat earnings estimates for Q2 2025? MediciNova (NASDAQ:MNOV) reported earnings of -$0.07 per share for Q2 2025, matching the consensus estimate of -$0.07. The report was announced on Thursday, August 14, 2025. What was MediciNova's revenue for Q2 2025? MediciNova reported revenue of $140 thousand for Q2 2025. MediciNova Earnings HeadlinesMedicinova IncNovember 14, 2026 | money.usnews.comMediciNova to Participate in the Maxim Growth SummitOctober 6, 2026 | globenewswire.comChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when trying to reach their money. The outage lasted hours. Cedar Gold Group points out that physical gold has no login, no server and needs no one's permission. Its free Wealth Protection Playbook shows how to keep part of your savings outside the banking system.November 19 at 1:00 AM | Cedar Gold Group (Ad)MediciNova stock tumbles on mixed Phase 2 NAFLD trial dataSeptember 28, 2026 | finance.yahoo.comMediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary EndpointsSeptember 28, 2026 | finance.yahoo.comMediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In PremarketSeptember 28, 2026 | rttnews.comSee More MediciNova Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email. Email Address About MediciNovaMediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines. MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.View MediciNova ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.